A non-invasive method for detection of intestinal mucositis induced by different classes of chemotherapy drugs in the rat

Cancer Biology and Therapy

Volumn 5, Issue 9, 2006, Pages 1189-1195

  Howarth, Gordon S ^a,b,c,d,e   Tooley, Katie L ^a,b   Davidson, Geoffrey P ^a,b   Butler, Ross N ^a,b,f  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

^e Nidor Pty Ltd   (Australia)

^f Centre for Paediatric and Adolescent Gastroenterology   (Australia)

Author keywords

Breath test; Chemotherapy; Mucositis; Non invasive; Sucrose

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; SUCROSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREATH ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; ENTERITIS; FEMALE; HISTOPATHOLOGY; MUCOSA INFLAMMATION; NONHUMAN; RAT; SCORING SYSTEM;

EID: 33751115718     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.9.3117     Document Type: Article

References (33)

1. Saadeh CE. Chemotherapy-and radiotherapy-induced oral mucositis: Review of preventive strategies and treatment. Pharmacotherapy 2005; 25:540-54.
2. Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis and diarrhoea. Lancet Oncol 2005; 6:96-102.
3. Lutgens LC, Blijlevens NM, Deutz NE, Donnelly JP, Lambin P, de Pauw BE. Monitoring myeloblative therapy-induced small bowel toxicity by serum citrulline concentration: A comparison with sugar permeability tests. Cancer 2005; 103:191-9.
4. 13C-octanoic acid breath test. Clin Exp Pharmacol Physiol 2000; 27:671-5.
5. Lin HC, Prather C, Fisher RS, Meyer JH, Summers RW, Pimentel M, McCallum RW, Akkermans LM, Loening-Baucke V. AMS task force committee on gastrointestinal transit. Measurement of gastrointestinal transit. Dig Dis Sci 2005; 50:989-1004.
6. Semenza G, Brunner J, Wacker H. Biosynthesis and assembly of the largest and major intrinsic polypeptide of the small intestinal brush borders. Ciba Found Symp 1983; 95:92-112.
7. Pelton NS, Tivey DR, Howarth GS, Davidson GP, Butler RN. A novel breath test for the noninvasive assessment of small intestinal mucosal injury following methotrexate administration in the rat. Scand J Gastroenterol 2004; 39:1015-6.
8. Clarke JM, Pelton NS, Bajka BH, Howarth GS, Read LC, Butler RN. Use of the sucrose breath test to assess chemotherapy-induced mucositis in the rat. Cancer Biol Ther 2006; 5:34-8.
9. Tooley KL, Howarth GS, Lymn K, Lawrence A, Butler RN. Oral ingestion of Streptococcus thermophilus diminishes severity of small intestinal mucositis in methotrexate treated rats. Cancer Biol Therap 2006; In press.
10. Cool JC, Dyer JL, Xian CJ, Butler RN, Geier MS, Howarth GS. Pretreatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Hormone and IGF Research 2005; 15:72-82.
11. Blay JY, Le Cesne A, Alberti L, Ray-Coquart I. Targeted cancer therapies. Bull Cancer 2005; 92:E13-E8.
12. Bailly C, Barret JM, Kruczynski A. Antitumor pharmacology - quo vadis? Curr Med Chem Anti-Canc Agents 2004; 4:389-91.
13. Tomas FM, Knowles SE, Owens PC, Read LC, Chandler CS, Gargosky SE, Ballard FJ. Effects of full-length and truncated insulin-like growth factor-I on nitrogen balance and muscle protein metabolism in nitrogen-restricted rats. J Endocrinol 1991; 128:97-105.
14. Guffroy M, Hodge T. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 1996; 88:1240-1.
15. Morelli D, Menard S, Lolnaghi MI, Balsari A. Oral administration of anti-doxirubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res 1996; 56:2082-5.
16. Johansson JE, Soussi B, Bagge U, Ekman T. Disturbance of purine nucleotide metabolism: A possible early key event in development of intestinal damage induced by chemotherapy. Dig Dis Sci 2001; 46:257-61.
17. Satoh J, Tsujikawa T, Fujiyama Y, Bamba T. Nutritional benefits of enteral alanyl-glutamine supplementation on rat small intestinal damage induced by cyclophosphamide. J Gastroenterol Hepatol 2003; 18:719-25.
18. Steeb CB, Lamb J, Shoubridge CA, Tivey DR, Penttila I, Read LC. Systemically but not orogastrically delivered insulin-like growth factor (IGF-I) and long [Arg3]IGF-I stimulates intestinal disaccharidase activity in two age groups of suckling rats. Pediatr Res 1998; 44:663-72.
19. Krawisz JE, Sharon SP, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984; 87:1344-50.
20. Howarth GS, Francis GL, Cool JC, Xu X, Byard RW, Read LC. Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 1996; 126:2519-30.
21. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-10.
22. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999; 8:135-60.
23. Howarth GS, Cool JC, Bourne AJ, Ballard FJ, Read LC. Insulin-like growth factor-I (IGF-I) simulates regrowth of the damaged intestine in rats, when administered following, but not concurrent with, methotrexate. Growth Factors 1998; 15:279-92.
24. Bailly C. Homocamptothecins: Potent topoisomerase I inhibitors and promising anticancer drugs. Crit Rev Oncol Hematol 2003; 45:91-108.
25. Glimelius B. Benefit-risk assessment of irinotecan in advanced colorectal cancer. Drug Saf 2005; 28:417-33.
26. Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DMK. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003; 18:1095-100.
27. Dorr W, Reichel S, Spekl K. Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation. Radiother Oncol 2005; 75:99-105.
28. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 2001; 61:687-93.
29. Booth C, Booth D, Williamson S, Demchyshyn LL, Potten CS. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif 2004; 37:385-400.
30. Clarke J, Butler R, Howarth G, Read L, Regester G. Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster. Oral Oncol 2002; 38:478-85.
31. Tran CD, Howarth GS, Coyle P, Philcox JC, Rofe AM, Butler RN. Dietary supplementation with zinc and a growth factor extract derived from bovine cheese whey improves methotrexate-damaged rat intestine. Am J Clin Nutr 2003; 77:1296-303.
32. Xian CJ. Roles of growth factors in chemotherapy-induced intestinal mucosal damage repair. Curr Pharm Biotechnol 2003; 4:260-9.
33. Harsha WT, Kalandarova E, McNutt P, Irwin R, Noel J. Nutritional supplementation with transforming growth factor-beta, glutamine, and short chain fatty acids minimizes methotrexate-induced injury. J Pediatr Gastroenterol Nutr 2006; 42:53-8.